AGTC Announces New Data Supporting Novel Gene-Based

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
AGTC Announces New Data Supporting Novel Gene-Based Therapies for Rare Inherited Retinal Diseases

NEW ORLEANS, May 18, 2015 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC ), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced new preclinical data which further supports the safety of the company's AAV vector gene therapies for the treatment of achromatopsia (ACHM) and X-linked retinoschisis (XLRS). Additionally, new safety data were presented on AGTC's proprietary manufacturing process. Study results were presented at the American Society of Gene & Cell Therapy (ASGCT) 18th Annual Meeting, which took place from May 13 – 16, in New Orleans.

"We are encouraged by these study results that further underscore the safety of novel AAV-based gene therapies to treat rare inherited eye diseases with few currently available therapeutic options," said Sue Washer, President and CEO of AGTC. "Furthermore, new data on our proprietary vector manufacturing process suggest that patients receiving rAAV vectors purified in this manner have a very low risk of HSV-related adverse events, and support the continued development of these vectors in the treatment of human disease."

Title: Safety and Biodistribution Study of rAAV2tYF-CB-hRS1 in RS1-deficient Mice
Abstract #: 350775
Presenting Author: Jeffrey D. Chulay, M.D., DTM&H

This study evaluated the toxicology and biodistribution profiles of a recombinant adeno-associated virus (rAAV) vector expressing the human retinoschisin (hRS1) gene at two doses in three groups of male RS1-deficient mice. Results demonstrated that intravitreal injection of rAAV2tYF-CB-hRS1 was well tolerated with minimal ocular inflammatory cells detected by histopathology. RS1 expression, measured by immunohistochemistry, was associated with decreased severity of splitting and disorganization of the inner nuclear layer of the retina at the higher dose level, supporting the use of this vector in patients with XLRS.

Title: Safety and Biodistribution Study of rAAV2tYF-CB-hRS1 in Nonhuman Primates
Abstract #: 350780
Presenting Author: Jeffrey D. Chulay, M.D., DTM&H

This study evaluated the toxicology and biodistribution of an AAV vector expressing retinoschisin in male cynomolgus macaques. Results demonstrated that administration of rAAV2tYF-CB-hRS1 in normal cynomolgus macaques was associated with dose-related anterior and posterior segment inflammatory response that improved over time. Histological examination revealed that mononuclear cell infiltrates of minimal to moderate intensity were more common in the higher dose group and RS1 expression in the retinal ganglion cell ring was demonstrated by immunohistochemistry. These results further support the use of rAAV2tYF-CB-hRS1 in clinical studies of patients with XLRS.

Title: Initial Safety Evaluation of rAAV-hCNGB3 Vectors in Nonhuman Primates
Abstract #: 350277
Presenting Author: Guo-jie Ye, Ph.D.

Previous studies in CNGB3-mutant dogs have shown that subretinal injection of an AAV5 vector expressing a human CNGB3 gene can rescue the ACHM electroretinography (ERG) phenotype, but also showed that at high doses, many of the animals developed chorioretinitis, a toxicity consistent with an immune response to a foreign protein. This study evaluated eight cynomolgus macaques that received subretinal injections of AAV2tYF-hCNGB3 or AAV5-hCNGB3 vectors, followed by ophthalmic examinations, digital fundus photography, scotopic and photopic ERG and visual evoked potentials (VEP) and histological examination. Results showed that both vectors were well tolerated and were associated with dose-related ocular inflammation that was milder than the severe inflammation seen in dogs receiving high dose of AAV5-hCNGB3. No test article-related effects on ERG or VEP were observed. These findings will be helpful for guiding future development of rAAV-CNGB3 gene therapies for humans.

Title: Efficient Clearance of Herpes Simplex Virus Using a GMP-compliant Method for Production of Recombinant Adeno-associated Virus Vectors
Abstract #: 350887
Presenting Author: Guo-jie Ye, Ph.D.

This study evaluated the safety of AGTC's proprietary, herpes simplex virus (HSV) manufacturing process for production of recombinant AAV virus vectors. Results demonstrated that the company's process to produce and purify rAAV vectors for use in patients with XLRS and ACHM effectively inactivates and removes HSV particles during vector production. The study authors concluded that the risk of HSV-related adverse events in patients receiving rAAV vectors purified in this manner is very low.

About AGTC

AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases in ophthalmology. AGTC's lead product candidates focus on X-linked retinoschisis, achromatopsia and X-linked retinitis pigmentosa, which are inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments. AGTC is also using its gene therapy expertise to expand into disease indications with large market opportunity such as wet AMD.

Forward Looking Statements

This release contains forward-looking statements that reflect AGTC's plans, estimates, assumptions and beliefs. Forward-looking statements include information concerning possible or assumed future results of operations, business strategies and operations, preclinical and clinical product development and regulatory progress, potential growth opportunities, potential market opportunities and the effects of competition. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as "anticipates," "believes," "could," "seeks," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" or similar expressions and the negatives of those terms. Actual results could differ materially from those discussed in the forward-looking statements, due to a number of important factors, including, without limitation, those described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2014, as filed with the SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent management's plans, estimates, assumptions and beliefs only as of the date of this release. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

David Carey Lazar Partners Ltd. T: (212) 867-1768 Corporate Contact: Larry Bullock Chief Financial Officer Applied Genetic Technologies Corporation T: (386) 462-2204

Scroll down for more posts ▼

Top 10 Most Recent News Articles

California Stone Ban Puts a Hidden Worker Toll in View

Updated Category News Views 42

Countertops are supposed to finish a kitchen, not quietly wreck the lungs of the people cutting them. Yet California's move toward prohibiting the fabrication and installation of artificial stone containing more than 1% crystalline silica puts an ugly, long-running occupational-health problem in plain sight. This is not a story that calls for chest-thumping market talk....

Continue Reading
Water Damage Coverage Has More Traps Than Homeowners Think

Updated Category News Views 29

A wet basement does not care one bit whether the water arrived dramatically or dripped in for months. That ugly distinction, though, can decide whether a homeowner has an insurance claim or a repair bill that lands with a thud. Kathy Thurmond-Edwards, an insurance expert in Memphis, Tennessee, lays out the dividing lines plainly: sudden pipe failures may be treated very...

Continue Reading
ACP's 1-for-4 Split Raises Price, Not Investor Value Yet

Updated Category News Views 68

Four ACP shares are about to become one, and the calculator crowd is liable to make a mountain out of a bookkeeping move. abrdn Income Credit Strategies Fund will execute a 1-for-4 reverse split before the opening bell on December 7, 2026. The quoted share price should rise by roughly four times, but the economic stake held by an investor does not magically get bigger...

Continue Reading
Surf City Seasons Put Vacation Rental Timing in Focus

Updated Category News Views 28

Summer’s Calendar Does the Talking School bells, not seagulls, appear to set the pace for Surf City’s rental market. Chris Rackley’s seasonal guide makes a pretty grounded point: the “best” time to visit Surf City, North Carolina, is not some universal magic week on a postcard. It depends on whether a traveler needs peak beach weather, wants elbow room, or...

Continue Reading
Home Nursing Plans Need Clarity Before the Next Crisis

Updated Category News Views 71

A medication change scribbled on a loose sheet can become a very long night. That is the unglamorous truth behind the discussion from Michael and Marsha Reda of Aurora Home Care in Williamsville, New York: long-term home nursing care depends on a plan people can actually follow when the household is tired, worried, and juggling too much. Their perspective, featured by...

Continue Reading
Cash Flow Discipline Is Where Business Growth Gets Real

Updated Category News Views 73

A full order book can still leave a company gasping at payroll. That is the unglamorous point behind the Nov. 20, 2026, HelloNation piece featuring Kimberly Furrh of Furrh & Associates PC in Lawton, Oklahoma. Owners love to talk about sales because sales are visible, flattering and easy to celebrate. Cash is less theatrical. It is also the thing that keeps the lights on...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 116

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 110

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
Rosalind Franklin University’s $23.8M Scholarship Win

Updated Category News Views 80

Twenty-three million dollars can disappear fast in graduate health education, which is exactly why Rosalind Franklin University’s campaign result deserves more than a polite round of applause. The university’s five-year Empowering Scholars effort closed in June 2026 with $23,836,272 raised, clearing its $20 million target by roughly 19%. In a world where institutions...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 61

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading

Top 5 Most Recently Viewed Articles

Organon & Co. Class Action Lawsuit: Key Details You Should Know

Updated Category News Views 221

Overview of the Class Action Lawsuit Against Organon & Co. The latest developments in the class action lawsuit regarding Organon & Co. (NYSE: OGN) have attracted attention from investors. The lawsuit is aimed at representing purchasers of Organon's publicly traded securities during a specific time frame. Robbins Geller Rudman & Dowd LLP has taken the lead in filing this...

Continue Reading
JINRO Partners with BTS's V: A Strategic Move

Updated Category News Views 25

What's Brewing Between JINRO and BTS's V? Picture this: you're wandering the aisles of an international market, see a splashy new bottle of soju, and notice V from BTS smiling from the label. That's right, folks, JINRO, the world's reigning soju brand, has just snagged a partnership with BTS's V to serve up a global brand punch. This move isn't just a pretty face on a...

Continue Reading
Latin Metals Unveils Exciting Spin-Out Plan for Copper Assets

Updated Category News Views 172

Latin Metals Moves Forward with Spin-Out of Peruvian Assets Latin Metals Inc. (TSXV: LMS, OTCQB: LMSQF) is charting a new course by announcing its decision to spin-out certain Peruvian exploration projects into a newly founded subsidiary named Latin Explore. This strategic move aims to unlock value for shareholders while maintaining a robust exploration agenda. Overview...

Continue Reading
McCormick's Resilience Shines Amidst Economic Challenges

Updated Category News Views 66

McCormick Challenges and Growth Strategy McCormick & Company, Inc. (NASDAQ: MKC) recently announced its third-quarter earnings, revealing a solid financial performance, even in a tough consumer environment. The company achieved a 1% volume growth in its Consumer segment and steady sales in its Flavor Solutions segment, showcasing a strong market presence despite...

Continue Reading
Goodyear's Financial Performance Amidst Industry Challenges

Updated Category News Views 248

Understanding Goodyear's Recent Earnings Report Goodyear Tire & Rubber Co (NASDAQ: GT) has reported its recent financial results, particularly highlighting the challenges faced during the second quarter of their fiscal year 2025. This period proved to be quite turbulent after the closing bell, reflecting considerable disruptions in their operating environment that...

Continue Reading